Contineum Therapeutics (CTNM) vs Fulcrum Therapeutics (FULC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 39.5% versus a loss of 59.4%. Fulcrum Therapeutics is the larger company by market cap ($278.8 million vs $266.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | FULC |
|---|---|---|
| Share price | $7.08 | $3.65 |
| Market cap | $266.36M | $278.79M |
| 1-day change | -10.38% | -0.54% |
| YTD return | -38.06% | -67.73% |
| 1-year return | -39.49% | -59.40% |
| 5-year return | — | -85.26% |
| EPS (TTM) | $-1.73 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-59.98M | $-74.88M |
| 52-week high | $17.79 | $15.74 |
| 52-week low | $6.95 | $2.83 |
| Distance from 52-week high | -60.19% | -76.81% |
| Analyst consensus | buy | none |
| Avg. price target upside | +212.71% | +0.55% |
| Average volume | 732.62K | 1.52M |
| Shares outstanding | 32.96M | 76.38M |
| Employees | 51 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTNM has outperformed FULC by 19.9 percentage points over the past year.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CTNM vs FULC FAQ
Which is bigger, Contineum Therapeutics or Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $278.79M compared with $266.36M for Contineum Therapeutics (CTNM).
Which stock has performed better over the past year, CTNM or FULC?
CTNM returned -39.49% over the past 12 months, compared with -59.40% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Contineum Therapeutics and Fulcrum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.